Advertisement

Topics

IFNα-Kinoid - Biotech, Pharma and Life Science Channel

00:56 EST 18th January 2017 | BioPortfolio

Lupus : A major unmet medical need

Lupus is a chronic and severe autoimmune disease in which the immune system produces antibodies to cells within the body leading to widespread inflammation and tissue damage. It may affect multiple organ systems, including the skin, the joints, the heart, the lungs and the kidneys. It can result in arthritis, kidney failure, cardio-vascular and pulmonary problems, nervous system disorders, inflammation of the circulatory system and hematologic abnormalities. Lupus is a life-threatening disease, with mortality most frequently a result of secondary effects of the disease, most commonly glomerular nephritis leading to kidney failure. Lupus disease may first occur at any age, though peak diagnosis is between the ages of 15 and 40. It is far more common in women than men: approximately 90% of cases are diagnosed in women. Prevalence estimates for the disease vary widely, and range as high as 1.5 million in North America (the Lupus Foundation of America) and 5 million worldwide.

There is currently no targeted therapy for lupus: rather the treatment strategy is to control symptoms and prevent disease flares. This strategy relies on the use of corticosteroids and immunosuppressants, which have significant tolerability and toxicity issues in a chronic use setting. Some biologics are also used off-label, but their efficacy appears modest.

Source: http://www.neovacs.fr/en/products/IFNa-Kinoide

News Articles [11 Associated News Articles listed on BioPortfolio]

Neovacs to participate in two upcoming investor events in the United States and France

PRESS RELEASE· PRESS RELEASE· PRESS RELEASE Neovacs to participate in two upcoming investor events in the United States and France Company to conduct investor meetings at LifeSci Adv...

NEOVACS to collaborate with the SUNNYBROOK RESEARCH INSTITUTE for preclinical development of VEGF Kinoid to treat colorectal cancer and ovarian cancer

PRESS RELEASE· PRESS RELEASE· PRESS RELEASE NEOVACS to collaborate with the SUNNYBROOK RESEARCH INSTITUTE for preclinical development of  VEGF Kinoid to treat  

Neovacs to collaborate with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal cancer and ovarian cancer

PARIS and BOSTON, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapies for the treatment of autoimmune diseases, today announced its collaboration ...

NEOVACS obtains FDA "Fast Track" designation for IFNalpha Kinoid in Lupus (SLE)

PRESS RELEASE· PRESS RELEASE· PRESS RELEASE Neovacs obtains FDA "Fast Track" designation for IFNalpha Kinoid in Lupus (SLE) Paris and Boston, December 7, 2016 - Neova...

Neovacs obtains FDA “Fast Track” designation for IFNα Kinoid in Lupus (SLE)

PARIS and BOSTON, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that the U.S. Foo...

Neovacs signs production partnership with 3P Biopharmaceuticals, a leading GMP producer of biological drugs

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs signs production partnership with 3P Biopharmaceuticals, a leading GMP producer of biological drugs Agreement addresses future p...

Neovacs SA ALNEV Financial and Strategic SWOT Analysis Review Prices from USD $300

SummaryNeovacs SA Neovacs a subsidiary of Truffle Capital is a biotechnology company that develops various vaccines. The company offers TNF Kinoid and IFNa Kinoid products used in cure of Rheumatoid a...

Neovacs acquires interferon alpha manufacturing technology from AMEGABIOTECH

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs acquires interferon alpha manufacturing technology from AMEGABIOTECH  Acquisition significantly strengthens the strategy for c...

Neovacs enrolls the first U.S. Patient in Phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus (SLE)

  PRESS RELEASE· PRESS RELEASE· PRESS RELEASE Neovacs enrolls the first U.S. Patient in Phase IIb study of IFNalpha Kinoid for treatment of Systemic Lupus Erythematosus (SLE) St...

NEOVACS: half-year results 2016 and update on operational development

 PRESS RELEASE ·  PRESS RELEASE  · PRESS RELEASE HALF-YEAR RESULTS 2016AND UPDATE ON OPERATIONAL DEVELOPMENT Cash position significantly strengthened by successful capital inc...

Events [0 Results]

None

Companies [0 Results]

None

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

Study of IFN-K in Dermatomyositis

This study is a Proof of Concept study aiming to evaluate the production of anti-IFNα antibodies (immune response) in adult subjects with dermatomyositis

Study of IFN-K in Systemic Lupus Erythematosus

The safety and immunogenicity of the IFN-Kinoid (IFN-K) have been evaluated in a phase I clinical study conducted in subjects with SLE. Preliminary results were promising. The principal a...

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa 2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-...

Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer

Influenza vaccination reduces the morbidity and mortality associated with influenza infection in at risk groups including the elderly and individuals with an impaired immune response, but...

Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists and ADA

The objective of this trial is to demonstrate that active immunization with anti-TNFα kinoid (TNF-K) is able to induce polyclonal anti-TNFα antibodies in RA patients who were previously ...

Safety of IFNa Kinoid in Systemic Lupus Erythematosus

Interferon alpha (IFNa) is involved in the pathogenesis of systemic lupus erythematosus (SLE)and IFNa levels are associated with the severity of the disease. Blocking IFNa could be an attr...

Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease

Evaluation of the safety and the immune response induced by active immunization through a TNFa kinoid in patients with Crohn's disease.

PubMed Articles [0 Results]

None

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.

Quick Search
Advertisement
 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Lupus
Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

review and buy IFNα-Kinoid market research data and corporate reports here

Channels Quicklinks